Thanks CJ! now I have some reading to do : ) Peregrine sure did sound confident on this conference call and no way they start a breast cancer trial unless the stars are all aligning properly at this time.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!